Immunotherapy for allergies and asthma: present and future.
Allergen immunotherapy (IT) is a proven approach for treating allergic rhinitis and allergic asthma that has been practiced since 1911 and has undergone significant development in the past two decades. As currently practiced, IT involves subcutaneous or sublingual administration of allergens, both methods of which have been extensively investigated. In addition to allergen IT, a number of additional nonspecific IT approaches are being used or are in phase II/phase III clinical trials, which may be available in clinics within the next one to three years. Such therapies include anti-IgE antibodies and the soluble IL-4 receptor. Other experimental IT approaches are at the preclinical research stage and may proceed to clinical trials and the clinic within the next five to ten years. This review discusses the pros and cons of recent developments in both currently practiced and experimental IT approaches.
Mohapatra
Shyam S
SS
Department of Internal Medicine, Division of Allergy and Immunology, University of South Florida College of Medicine, Tampa, FL, USA. smohapat@health.usf.edu
Qazi
Momina
M
Hellermann
Gary
G
D000485:Allergens / Q000276:immunology; D000818:Animals; D001249:Asthma / Q000276:immunology / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology / Q000628:therapy*; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D012221:Rhinitis, Allergic, Perennial / Q000276:immunology / Q000628:therapy; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology / Q000628:therapy
D000485:Allergens